Stockreport
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC).Conference call details:Monday June 17, 20248:30 a.m. ET / 5:30 a.m. PTDial-in:U.S./Toll-Free: +1 833 470 1428International: +1 404 975 4839Passcode: 205511You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.About Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol)
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) was upgraded by analysts at Baird R W to a "strong-buy" rating.[MarketBeat]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at JPMorgan Chase & Co. from $31.00 to $39.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $38.00 to $64.00. They now have a "buy" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at JMP Securities from $66.00 to $68.00. They now have a "market outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Morgan Stanley from $53.00 to $57.00. They now have an "overweight" rating on the stock.[MarketBeat]
- More
MIRM
SEC Filings
SEC Filings
- 6/25/24 - Form 4
- 6/24/24 - Form 144
- 6/17/24 - Form 8-K
- MIRM's page on the SEC website
- More